Comparison of metabolic changes after neoadjuvant endocrine and chemotherapy in ER-positive, HER2-negative breast cancer

Abstract Survival of breast cancer patients has improved, and treatment-related changes regarding metabolic profile deterioration after neoadjuvant systemic treatment (NST) become important issues in cancer survivors. We sought to compare metabolic profile changes and the neutrophil-to-lymphocyte ra...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ho Hyun Ryu, Sei Hyun Ahn, Seon Ok Kim, Jeong Eun Kim, Ji sun Kim, Jin-Hee Ahn, Kyung Hae Jung, Sung-Bae Kim, Beom Seok Ko, Jong Won Lee, Byung Ho Son, Hee Jung Shin, Hak Hee Kim, Gyung yub Gong, Hee Jeong Kim
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/2e12df5d86484ac796ec0eb06330249b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2e12df5d86484ac796ec0eb06330249b
record_format	dspace
spelling	oai:doaj.org-article:2e12df5d86484ac796ec0eb06330249b2021-12-02T15:45:16ZComparison of metabolic changes after neoadjuvant endocrine and chemotherapy in ER-positive, HER2-negative breast cancer10.1038/s41598-021-89651-02045-2322https://doaj.org/article/2e12df5d86484ac796ec0eb06330249b2021-05-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-89651-0https://doaj.org/toc/2045-2322Abstract Survival of breast cancer patients has improved, and treatment-related changes regarding metabolic profile deterioration after neoadjuvant systemic treatment (NST) become important issues in cancer survivors. We sought to compare metabolic profile changes and the neutrophil-to-lymphocyte ratio (NLR) between patients undergoing neoadjuvant chemotherapy (NCT) and neoadjuvant endocrine therapy (NET) 3 years after the treatment. In a prospective, randomized, phase III trial which compared 24 weeks of NCT with adriamycin and cyclophosphamide followed by docetaxel and NET with goserelin and tamoxifen (NEST), 123 patients in the Asan Medical Center were retrospectively reviewed to evaluate metabolic changes, such as body mass index (BMI), blood pressure (BP), total cholesterol (TC), fasting glucose, and the NLR. The mean age of patients was 42 years. The changes in BMI, serum glucose, and TC during NST and after 3 years were significantly different between NCT and NET. The proportion of overweight + obese group and the mean BMI were significantly increased during NCT (26.6% to 37.5%, 22.84 kg/m2 to 23.87 kg/m2, p < 0.05), and these attributes found to have normalized at the 3-year follow-up. In the NET group, BMI changes were not observed (p > 0.05, all). There were no differences in changes over time among in the Hypertension group during NCT and NET (p = 0.96). The mean value of serum TC and fasting glucose significantly increased (< 0.05, both) during NCT and decreased 3 years after NCT (p < 0.05); however, no significant changes were observed in the NET group. The NLR was increased from 1.83 to 3.18 after NCT (p < 0.05) and decreased from 1.98 to 1.43 (p < 0.05) after NET. Compared with minimal metabolic effect of NET, NCT worsens metabolic profiles, which were recovered over 3 years. The NLR was increased after NCT but decreased after NET.Ho Hyun RyuSei Hyun AhnSeon Ok KimJeong Eun KimJi sun KimJin-Hee AhnKyung Hae JungSung-Bae KimBeom Seok KoJong Won LeeByung Ho SonHee Jung ShinHak Hee KimGyung yub GongHee Jeong KimNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Ho Hyun Ryu Sei Hyun Ahn Seon Ok Kim Jeong Eun Kim Ji sun Kim Jin-Hee Ahn Kyung Hae Jung Sung-Bae Kim Beom Seok Ko Jong Won Lee Byung Ho Son Hee Jung Shin Hak Hee Kim Gyung yub Gong Hee Jeong Kim Comparison of metabolic changes after neoadjuvant endocrine and chemotherapy in ER-positive, HER2-negative breast cancer
description	Abstract Survival of breast cancer patients has improved, and treatment-related changes regarding metabolic profile deterioration after neoadjuvant systemic treatment (NST) become important issues in cancer survivors. We sought to compare metabolic profile changes and the neutrophil-to-lymphocyte ratio (NLR) between patients undergoing neoadjuvant chemotherapy (NCT) and neoadjuvant endocrine therapy (NET) 3 years after the treatment. In a prospective, randomized, phase III trial which compared 24 weeks of NCT with adriamycin and cyclophosphamide followed by docetaxel and NET with goserelin and tamoxifen (NEST), 123 patients in the Asan Medical Center were retrospectively reviewed to evaluate metabolic changes, such as body mass index (BMI), blood pressure (BP), total cholesterol (TC), fasting glucose, and the NLR. The mean age of patients was 42 years. The changes in BMI, serum glucose, and TC during NST and after 3 years were significantly different between NCT and NET. The proportion of overweight + obese group and the mean BMI were significantly increased during NCT (26.6% to 37.5%, 22.84 kg/m2 to 23.87 kg/m2, p < 0.05), and these attributes found to have normalized at the 3-year follow-up. In the NET group, BMI changes were not observed (p > 0.05, all). There were no differences in changes over time among in the Hypertension group during NCT and NET (p = 0.96). The mean value of serum TC and fasting glucose significantly increased (< 0.05, both) during NCT and decreased 3 years after NCT (p < 0.05); however, no significant changes were observed in the NET group. The NLR was increased from 1.83 to 3.18 after NCT (p < 0.05) and decreased from 1.98 to 1.43 (p < 0.05) after NET. Compared with minimal metabolic effect of NET, NCT worsens metabolic profiles, which were recovered over 3 years. The NLR was increased after NCT but decreased after NET.
format	article
author	Ho Hyun Ryu Sei Hyun Ahn Seon Ok Kim Jeong Eun Kim Ji sun Kim Jin-Hee Ahn Kyung Hae Jung Sung-Bae Kim Beom Seok Ko Jong Won Lee Byung Ho Son Hee Jung Shin Hak Hee Kim Gyung yub Gong Hee Jeong Kim
author_facet	Ho Hyun Ryu Sei Hyun Ahn Seon Ok Kim Jeong Eun Kim Ji sun Kim Jin-Hee Ahn Kyung Hae Jung Sung-Bae Kim Beom Seok Ko Jong Won Lee Byung Ho Son Hee Jung Shin Hak Hee Kim Gyung yub Gong Hee Jeong Kim
author_sort	Ho Hyun Ryu
title	Comparison of metabolic changes after neoadjuvant endocrine and chemotherapy in ER-positive, HER2-negative breast cancer
title_short	Comparison of metabolic changes after neoadjuvant endocrine and chemotherapy in ER-positive, HER2-negative breast cancer
title_full	Comparison of metabolic changes after neoadjuvant endocrine and chemotherapy in ER-positive, HER2-negative breast cancer
title_fullStr	Comparison of metabolic changes after neoadjuvant endocrine and chemotherapy in ER-positive, HER2-negative breast cancer
title_full_unstemmed	Comparison of metabolic changes after neoadjuvant endocrine and chemotherapy in ER-positive, HER2-negative breast cancer
title_sort	comparison of metabolic changes after neoadjuvant endocrine and chemotherapy in er-positive, her2-negative breast cancer
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/2e12df5d86484ac796ec0eb06330249b
work_keys_str_mv	AT hohyunryu comparisonofmetabolicchangesafterneoadjuvantendocrineandchemotherapyinerpositiveher2negativebreastcancer AT seihyunahn comparisonofmetabolicchangesafterneoadjuvantendocrineandchemotherapyinerpositiveher2negativebreastcancer AT seonokkim comparisonofmetabolicchangesafterneoadjuvantendocrineandchemotherapyinerpositiveher2negativebreastcancer AT jeongeunkim comparisonofmetabolicchangesafterneoadjuvantendocrineandchemotherapyinerpositiveher2negativebreastcancer AT jisunkim comparisonofmetabolicchangesafterneoadjuvantendocrineandchemotherapyinerpositiveher2negativebreastcancer AT jinheeahn comparisonofmetabolicchangesafterneoadjuvantendocrineandchemotherapyinerpositiveher2negativebreastcancer AT kyunghaejung comparisonofmetabolicchangesafterneoadjuvantendocrineandchemotherapyinerpositiveher2negativebreastcancer AT sungbaekim comparisonofmetabolicchangesafterneoadjuvantendocrineandchemotherapyinerpositiveher2negativebreastcancer AT beomseokko comparisonofmetabolicchangesafterneoadjuvantendocrineandchemotherapyinerpositiveher2negativebreastcancer AT jongwonlee comparisonofmetabolicchangesafterneoadjuvantendocrineandchemotherapyinerpositiveher2negativebreastcancer AT byunghoson comparisonofmetabolicchangesafterneoadjuvantendocrineandchemotherapyinerpositiveher2negativebreastcancer AT heejungshin comparisonofmetabolicchangesafterneoadjuvantendocrineandchemotherapyinerpositiveher2negativebreastcancer AT hakheekim comparisonofmetabolicchangesafterneoadjuvantendocrineandchemotherapyinerpositiveher2negativebreastcancer AT gyungyubgong comparisonofmetabolicchangesafterneoadjuvantendocrineandchemotherapyinerpositiveher2negativebreastcancer AT heejeongkim comparisonofmetabolicchangesafterneoadjuvantendocrineandchemotherapyinerpositiveher2negativebreastcancer
_version_	1718385739500093440

Comparison of metabolic changes after neoadjuvant endocrine and chemotherapy in ER-positive, HER2-negative breast cancer

Ejemplares similares